Biosimilar vs. Biologics: Comprehensive Review

Ali McBride, PharmD, MS, BCPS, BCOP
Clinical Coordinator, Hematology /Oncology
The University of Arizona Cancer Center
Department of Pharmacy
Tucson, Arizona

Recorded during "Treating Inflammatory Disease with Biosimilars: What Every GI Specialist Should Know" at the ACG Annual Scientific Meeting* in Honolulu on October 17, 2015.
*This program is neither sponsored nor endorsed by the ACG

Biosimilars: Payer and Formulary Considerations

Ross M. Miller, MD, MPH, FACPE
Medical Advisor
California Department of Health Care Services
Los Angeles, California
 
 

Biosimilars: The New Era of Gastroenterology Management Considerations, Part 1: Fundamentals

Kenneth McQuaid, MD
UCSF School of Medicine

Edward Li, PharmD, MPH, BCOP
University of New England College of Pharmacy

Cathleen Shellnutt, MSN, RN, AGCNS-BC, CGRN
Medical City Plano

Biosimilars: The New Era of Gastroenterology Management Considerations, Part 2: Biosimilars and Patients with Inflammatory Bowel Disease

Kenneth McQuaid, MD
UCSF School of Medicine

Edward Li, PharmD, MPH, BCOP
University of New England College of Pharmacy

Catherine Bauer, MSN, RN, MBA, CGRN, CFER
University of Virginia Medical Center

Clinician and Payer Perspectives on the First Biosimilar Approved in the US

CME/CE Multimedia Modules

Welcome to Biologics and Biosimilars: Preparing for the Future!

This is a series of 8 interactive modules. Each module focuses on a different topic and answers questions clinicians commonly ask about biosimilars. It is highly recommended that you complete the entire curriculum.

Comprehensive Review of Biosimilars vs. Reference Biologics

Jonathan Kay, MD
Director of Clinical Research
Rheumatology Division
UMASS Memorial Medical Center
Professor of Medicine
University of Massachusetts Medical School
Worcester, Massachusetts
 

Interchangeability and Extrapolation: Important Concepts Related to the Use of Biosimilars in Clinical Practice

Sanjiv S. Agarwala, MD
Chief, Oncology & Hematology
St. Luke’s University Health Network
Professor of Medicine
Temple University
Philadelphia, Pennsylvania

Interview: Expert Perspective on Biosimilars

Sanjiv S. Agarwala, MD
Chief, Oncology & Hematology
St. Luke’s University Health Network
Professor of Medicine
Temple University
Philadelphia, Pennsylvania

Pinpointing the Top Questions and Considerations about Biosimilars

This set of highly interactive, specialty-specific modules developed on the ArcheMedX ArcheViewer will enlighten participants on how to confidently evaluate and consider the use of biosimilars at the point of care. This series is customized for different clinical specialties, to provide patient and practice-specific biosimilars content for clinicians in dermatology, rheumatology, gastroenterology, and hematology/oncology practice.

Play

The Fundamentals of Biosimilar Regulation and Development in the US

Edward Li, PharmD, MPH, BCOP
Associate Professor
University of New England College of Pharmacy
Portland, Maine
 

Treating Inflammatory Bowel Disease with Biosimilars: What Will this Mean for the Clinician and the Patient?

Bruce Yacyshyn, MD, FACG
Professor of Medicine
Division of Digestive Diseases
University of Cincinnati
Cincinnati, Ohio

Recorded during "Treating Inflammatory Disease with Biosimilars: What Every GI Specialist Should Know" at the ACG Annual Scientific Meeting* in Honolulu on October 17, 2015. 
*This program is neither sponsored nor endorsed by the ACG

Updates on Regulation and Development

Sanjiv S. Agarwala, MD
Chief, Oncology & Hematology
St. Luke’s University Health Network
Professor of Medicine
Temple University
Philadelphia, Pennsylvania

Recorded during "Treating Inflammatory Disease with Biosimilars: What Every GI Specialist Should Know" at the ACG Annual Scientific Meeting* in Honolulu on October 17, 2015. *This program is neither sponsored nor endorsed by the ACG